Market activity in early summer has been a tug of war between optimism and uncertainty. In May 2025, markets staged an impressive comeback following the April sell-off. The S&P 500 posted its ...
Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer’s disease (AD) enrolled in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results